Vertex Pharmaceuticals History

FDA, Vertex Pharmaceuticals

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

Hosted on MSN · 1h

FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

Yahoo · 1h

FDA approves first non-addictive pain medication

The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to treat adults with acute pain. The medication is the first of its kind, with non-addictive properties and provides an alternative to opioids.

Vertex Pharmaceuticals price target raised to $550 from $535 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...

Seeking Alpha3d

VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

AFP7h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX

NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results